INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26801, 13517, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26802, 13518, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26803, 13519, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26804, 13520, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26805, 13521, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26806, 25434, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26807, 28422, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26808, 29518, 'Tacrolimus', 'Long QT Syndrome', 'Tacrolimus may prolong the QT/QTc interval and may cause Torsade de Pointes.  It is recommended to avoid tacrolimus in patients with congenital long QT syndrome.  In patients with congestive heart failure, bradyarrhythmias, those taking certain antiarrhythmic medications or other medicinal products that lead to QT prolongation, and those with electrolyte disturbances such as hypokalemia, hypocalcemia, or hypomagnesemia, consider monitoring of tacrolimus whole blood concentrations and obtaining electrocardiograms and monitoring electrolytes (magnesium, potassium, calcium) periodically during treatment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26809, 11196, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26810, 13242, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26811, 13502, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26812, 13503, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26813, 13504, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26814, 13514, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26815, 13515, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26816, 13516, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26817, 13517, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26818, 13518, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26819, 13519, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26820, 13520, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26821, 13521, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26822, 25434, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26823, 28422, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26824, 29518, 'Tacrolimus', 'Kidney Diseases', 'Nephrotoxicity has been reported in 52% of kidney and 40% of liver transplant patients.  Renal toxicity includes increasing serum creatinine and blood urea nitrogen, and renal failure sometimes requiring hemodialysis.  Oliguria and hematuria also have been reported.  The mechanism of tacrolimus-induced renal dysfunction is not well established.  Renal toxicity appears to be dose-related, although toxicity may still occur even at suggested therapeutic concentrations.  Therapy with tacrolimus should be administered cautiously and dosage reductions may be necessary in patients with compromised renal function.  Alternative immunosuppressive therapy should be considered in the presence of persistent or worsening renal dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26825, 11196, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26826, 13242, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26827, 13502, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26828, 13503, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26829, 13504, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26830, 13514, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26831, 13515, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26832, 13516, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26833, 13517, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26834, 13518, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26835, 13519, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26836, 13520, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26837, 13521, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26838, 25434, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26839, 28422, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26840, 29518, 'Tacrolimus', 'Hyperkalemia', 'The use of tacrolimus has been associated with hyperkalemia.  Therapy with tacrolimus should be administered cautiously in patients with elevated serum potassium levels.  Close monitoring of potassium levels is recommended.  Careful consideration should be given prior to use of other agents also associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin receptor blockers) during tacrolimus therapy.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26841, 11196, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26842, 13242, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26843, 13502, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26844, 13503, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26845, 13504, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26846, 13514, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26847, 13515, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26848, 13516, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26849, 13517, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26850, 13518, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26851, 13519, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26852, 13520, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26853, 13521, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26854, 25434, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26855, 28422, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26856, 29518, 'Tacrolimus', 'Hypertension', 'The use of tacrolimus has been associated with hypertension.  Therapy with tacrolimus should be administered cautiously in patients with elevated blood pressure.  Close monitoring of blood pressure is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26857, 6400, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26858, 16897, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26859, 20727, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26860, 27647, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26861, 27648, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26862, 27649, 'Sumatriptan', 'Coronary Artery Disease', 'The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease.  As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur.  Periodic cardiovascular evaluations should be performed during intermittent, long-term use.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26863, 6400, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26864, 16897, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26865, 20727, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26866, 27647, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26867, 27648, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26868, 27649, 'Sumatriptan', 'Cardiovascular Diseases', 'The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases.  In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension.  5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia.  Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD).  Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance.  Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities.  However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26869, 6400, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26870, 16897, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26871, 20727, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26872, 27647, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26873, 27648, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26874, 27649, 'Sumatriptan', 'Liver Diseases', 'The manufacturer considers the use of sumatriptan to be contraindicated in patients with severe hepatic impairment.  Sumatriptan is primarily metabolized by the liver.  Following subcutaneous administration, the pharmacokinetics of sumatriptan were not significantly altered in patients with hepatic impairment compared to healthy controls.  Following oral administration, however, the bioavailability was substantially increased compared to controls, presumably because the liver plays an important role in the presystemic clearance of orally administered sumatriptan.  The maximum single oral dose should generally not exceed 50 mg in patients with impaired hepatic function.  Data are not available for the nasal formulation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26875, 6400, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26876, 16897, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26877, 20727, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26878, 27647, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26879, 27648, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26880, 27649, 'Sumatriptan', 'Epilepsy', 'Seizures have rarely been reported following the administration of sumatriptan.  Therapy with sumatriptan should be administered cautiously in patients with epilepsy or a history of seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26881, 8949, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26882, 11153, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26883, 11155, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26884, 27883, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26885, 27884, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26886, 27885, 'Tamoxifen', 'Pulmonary Embolism', 'The use of tamoxifen is contraindicated in women with a history of deep vein thrombosis or pulmonary embolus or in women who require concomitant coumarin- type anticoagulant therapy.  There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, during tamoxifen therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26887, 8949, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26888, 11153, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26889, 11155, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26890, 27883, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26891, 27884, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26892, 27885, 'Tamoxifen', 'Endometrial Hyperplasia', 'Endometrial changes such as hyperplasia, polyps, and endometrial cancer have been reported during tamoxifen therapy.  Patients should be instructed to immediately report any signs or symptoms of uterine abnormality such as menstrual irregularities, abnormal vaginal bleeding, change in vaginal discharge, or pelvic pain or pressure.  Therapy with tamoxifen should be administered cautiously in patients with or history of gynecological abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26893, 8949, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26894, 11153, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26895, 11155, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26896, 27883, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26897, 27884, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26898, 27885, 'Tamoxifen', 'Liver Diseases', 'Tamoxifen is extensively metabolized by the liver and excreted in the feces.  Alteration in liver enzyme levels have been noted.  Severe hepatic injuries such as fatty liver, cholestasis, hepatitis, and hepatic necrosis are rare, however, deaths have been reported.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with tamoxifen should be administered cautiously in patients with or predisposed to compromised hepatic function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26899, 8949, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26900, 11153, 'Tamoxifen', 'Bone Marrow Failure Disorders', 'Hematological abnormalities during tamoxifen therapy may include thrombocytopenia, leukopenia, and anemia.  Rare hemorrhagic episodes, severe neutropenia and pancytopenia have been reported.  Therapy with tamoxifen should be administered cautiously to patients with or predisposed to bone marrow suppression.', '2', '', 'DDInter', 0);
